Introduction: Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid of blood cells marked by the proliferation of immature lymphocytes in large numbers. Thiosemicarbazones are noted for their biological activity and ability to function as ligands. The purpose of this research was to investigate the effect of thiosemicarbazones complexes with Cu on expression changes of LncRNA PCAT1 in the acute lymphoblastic leukemia Jurkat E6.1 cell line.
Methods: In this research, Appropriate doses of the thiosemicarbazones complexes Cu were prepared according to the IC50 of the drug that consists of 15 and 16 µM. The Jurkat E6.1 cell line was treated by Cu 72 hours after cell passage. The expression changes of LncRNA PCAT1 and GAPDH as the housekeeping gene were investigated using Real-Time PCR after RNA extraction and cDNA synthesis. Finally, Rest 2002 Software was used to analyze the data, and Excel was used to create diagrams.
Results: The Results of the research showed that after 72 hours of treatment with thiosemicarbazones complexes Cu at 15 and 16µM concentrations, the expression of LncRNA PCAT1 decreased significantly as compared to the control group. According to the findings, doses of 15 and 16µM of Cu over 72 hours are the optimal concentrations and time for this drug's effect. The expressions of LncRNA PCAT1 were 0/765 and 0/771 at the specified concentrations and times.
Conclusion: According to the findings of the study of expression changes in LncRNA PCAT1 after treatment with thiosemicarbazones complexes Cu, both concentrations of the drug were successful in decreasing LncRNA PCAT1 expression. Overall, thiosemicarbazones complexes Cu had a positive effect on the LncRNA PCAT1 oncogene reduction mechanism over 72hour, and this reduction in expressions was statistically meaningful (p-value 0.001). thiosemicarbazone complexes Cu has a high potential for cancer control and treatment, according to evidence.